STOCK TITAN

NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
NEXGEL, Inc. will report its financial results for Q4 and full year 2023 on March 28, 2024. The Company specializes in medical and OTC products, including hydrogels. A conference call will follow the release of financial results at 4:30 P.M. ET on the same day.
Positive
  • None.
Negative
  • None.

Management will host a conference call at 4:30 P.M. ET on the same day

LANGHORNE, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2023, after the market closes on March 28, 2024. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day.

Fourth Quarter and Full Year 2023 Financial Results Conference Call

Date: March 28, 2024
Time: 4:30 P.M. ET
Live Call: + 1-800-274-8461 (U.S. Toll Free) or + 1-203-518-9814 (International)
Webcast: Events and Presentations

For interested individuals unable to join the conference call, a replay will be available through April 11, 2024 by dialing + 1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 1155204. An archived version of the webcast will also be available for 90 days.

About NEXGEL, INC.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
valter@kcsa.com


FAQ

When will NEXGEL report its financial results for Q4 and full year 2023?

NEXGEL will report its financial results for Q4 and full year 2023 on March 28, 2024.

What products does NEXGEL specialize in?

NEXGEL specializes in medical and over-the-counter (OTC) products, including hydrogels.

When will the conference call following the financial results release take place?

The conference call will take place at 4:30 P.M. ET on the same day as the financial results release.

How can interested individuals access the replay of the conference call?

Interested individuals can access the replay of the conference call by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) with the code 1155204.

NEXGEL, Inc.

NASDAQ:NXGL

NXGL Rankings

NXGL Latest News

NXGL Stock Data

13.88M
4.93M
22.82%
2.03%
0.42%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States of America
LANGHORNE

About NXGL

nexgel advanced hydrogel solutions in a manufacturer of unique trans-dermal delivery system that was originally developed and fda-approved for the hospital wound care market, and is now being deployed against consumer otc, rx, medical device and cosmetic applications.